Inflammatory Bowel Disease Ulcerative Colitis Active Ulcerative Colitis Complementary Alternative Medicine Probiotic Product 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lilley DM, Stillwell RH. Probiotics: growth factors produced by microorganisms. Science 1965;147:747–748.CrossRefGoogle Scholar
  2. 2.
    FAO/WHO. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World health Organization Expert Consultation Report, 2001. http://www.fao.orgGoogle Scholar
  3. 3.
    Szajewska H, Setty M, Mrukowicz J, et al. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 2006;42:454–475.PubMedCrossRefGoogle Scholar
  4. 4.
    Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229–241.PubMedCrossRefGoogle Scholar
  5. 5.
    Lorenz RG, McCracken VJ, Elson CO. Animal models of intestinal inflammation: ineffective communication between coalition members. Springer Semin Immunopathol 2005;27:233–247.PubMedCrossRefGoogle Scholar
  6. 6.
    Li FX, Verhoef MJ, Best A, et al. Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. Can J Gastroenterol 2005;19: 567–573.Google Scholar
  7. 7.
    Quattropani C, Ausfeld B, Straumann A, et al. Complementary alternative medicine in patients with inflammatory bowel disease: use and attitudes. Scand J Gastroenterol 2003;38:277–282.PubMedCrossRefGoogle Scholar
  8. 8.
    Heuschkel R, Afzal N, Wuerth A, et al. Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol 2002;97:382–388.PubMedCrossRefGoogle Scholar
  9. 9.
    Day AS, Whitten KE, Bohane TD. Use of complementary and alternative medicines in children and adolescents with inflammatory bowel disease. J PaediatrChild Health 2004;40:681–684.Google Scholar
  10. 10.
    Hilsden RJ, Verhoef MJ, Best A, et al. Complementary and alternative medicine use in Canadian patients with inflammatory bowel disease: results of a national survey. Am J Gastroenterol 2003;98:1563–1568.PubMedCrossRefGoogle Scholar
  11. 11.
    Joos SS, Rosemann TT, Szecsenyi JJ, et al. Use of complementary and alternative medicine in Germany – a survey of patients with inflammatory bowel disease. BMC Complementary Alt Med 2006;6:19 doi:10.1186/1472–6882–6–19.CrossRefGoogle Scholar
  12. 12.
    Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20:1133–1141.PubMedCrossRefGoogle Scholar
  13. 13.
    Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100:1539–1546.PubMedCrossRefGoogle Scholar
  14. 14.
    Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697–698.PubMedCrossRefGoogle Scholar
  15. 15.
    Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. Gut 2005;54:242–249.PubMedCrossRefGoogle Scholar
  16. 16.
    Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute-mild-to-moderate ulcerative colitis. Med Sci Monit 2004;10:Pl126–Pl131.Google Scholar
  17. 17.
    Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the Ascend II trial. Am J Gastroenterol 2005;100:2478–2485.PubMedCrossRefGoogle Scholar
  18. 18.
    Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582–1592.PubMedCrossRefGoogle Scholar
  19. 19.
    Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853–858.PubMedCrossRefGoogle Scholar
  20. 20.
    Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lanect 1999;354:635–639.Google Scholar
  21. 21.
    Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103–1108.PubMedCrossRefGoogle Scholar
  22. 22.
    Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of Bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2002;22:56–63.Google Scholar
  23. 23.
    Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617–1623.PubMedCrossRefGoogle Scholar
  24. 24.
    Zocco MA, Zileri Dal Verme L, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23:1567–1574.PubMedCrossRefGoogle Scholar
  25. 25.
    Sandborn WJ. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord 2006;6:97–105.Google Scholar
  26. 26.
    Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003;17:509–515.PubMedCrossRefGoogle Scholar
  27. 27.
    Sandborn WJ, Tremaine WJ, Batss KP, et al. Pouchitis following ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 1994;69:409–415.PubMedGoogle Scholar
  28. 28.
    Laake KO, Bjorneklett A, Aamodt G, et al. Outcome of four weeks’ intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-con uration ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol 2005;40:43–51.PubMedCrossRefGoogle Scholar
  29. 29.
    Gotteland M, Poliak L, Cruchet S, et al. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus in children colonized with Helicobacter pylori. Acta Paediatr 2005;94:1747–1751.PubMedCrossRefGoogle Scholar
  30. 30.
    Gotteland M, Brusner O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori. Aliment Pharmacol Ther 2006;23:1077–1086.PubMedCrossRefGoogle Scholar
  31. 31.
    Pantoflickova D, Corthesy-Theulaz I, Dorta G, et al. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther 2003;18:805–813.PubMedCrossRefGoogle Scholar
  32. 32.
    Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastoenterology 2003;124:1202–1209.CrossRefGoogle Scholar
  33. 33.
    Gosselink MP, Schouten R, van Lieshout LMC, et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004;47:876–884.PubMedCrossRefGoogle Scholar
  34. 34.
    Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy a maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305–309.PubMedCrossRefGoogle Scholar
  35. 35.
    Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108–114.PubMedCrossRefGoogle Scholar
  36. 36.
    Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005;22:721–728.PubMedCrossRefGoogle Scholar
  37. 37.
    Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. Can Med Assoc J 2005;173:167–170.CrossRefGoogle Scholar
  38. 38.
    Benchimol EI, Mack DR. Probiotics for chronic and relapsing diarrhea. J Pediatr Hematol/Oncol 2004;26:515–517.CrossRefGoogle Scholar
  39. 39.
    Malchow H. Crohn’s disease and Escherichia coli: A new approach in therapy to maintain remission of colonic Crohn’s disease. J Clin Gastroenterol 1997;25:653–658.PubMedCrossRefGoogle Scholar
  40. 40.
    Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000;45:1462–1464.PubMedCrossRefGoogle Scholar
  41. 41.
    Gupta P, Andrew H, Kirschner BS, et al. Is Lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000;31:453–457.PubMedCrossRefGoogle Scholar
  42. 42.
    Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastoenterol 2004;4:5.CrossRefGoogle Scholar
  43. 43.
    Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis 2005;11:833–839.PubMedCrossRefGoogle Scholar
  44. 44.
    Gionchetti P, Amandini C, Rizzello F, et al. Probiotics for the treatment of postoperative complications following intestinal surgery. Best Prac Res Clin Gastroenterol 2003;17:821–831.CrossRefGoogle Scholar
  45. 45.
    Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995;108:856–861.CrossRefGoogle Scholar
  46. 46.
    Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomized controlled trial with Lactobacillus GG. Gut 2002;51:405–409.PubMedCrossRefGoogle Scholar
  47. 47.
    Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomized, double blind, placebo controlled GETAID trial. Gut 2006;55:842–847.PubMedCrossRefGoogle Scholar
  48. 48.
    Karimi O, Pena S, van Bodegraven AA. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn’s disease: a pilot study. Drugs Today 2005;41:453–459.PubMedCrossRefGoogle Scholar
  49. 49.
    Tamboli CP, Caucheteux C, Cortot A, et al. Probiotics in inflammatory bowel disease: a critical review. Best Prac Res Clin Gastroenterol 2003;17:805–820.CrossRefGoogle Scholar
  50. 50.
    Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2006;40:260–263.PubMedCrossRefGoogle Scholar
  51. 51.
    Huff BA. Caveat emptor. ‘Probiotics’ might not be what they seem. Can Family Physician 2004;50: 583–587.Google Scholar
  52. 52.
    Katz JA, Pirovano F, Matteuzzi D, et al. Commercially available probiotic preparations: are you getting what you pay for? Gastroenterology 2002;122:A459.Google Scholar
  53. 53.
    Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625–1634.PubMedCrossRefGoogle Scholar
  54. 54.
    Farina C, Arosio M, Mangia M, et al. Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 2001;33:251–252.PubMedCrossRefGoogle Scholar
  55. 55.
    Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr 2003;36:223–227.PubMedCrossRefGoogle Scholar
  56. 56.
    Prakash S, Martoni C. Toward a new generation of therapeutics: artificial cell targeted delivery of live cells for therapy. Appl Biochem Biotech 2006;128:1–22.CrossRefGoogle Scholar
  57. 57.
    Candelli M, Nista EC, Nestola M, et al. Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis. J Clin Gastroenterol 2003;36:39–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • David R. Mack
    • 1
  1. 1.Department of PediatricsUniversity of Ottawa, Head, Pediatric Gastroenterology, Hepatology & NutritionChildren’s Hospital of Eastern OntarioOttawaCANADA K1H 8L1

Personalised recommendations